ICON Public Limited Company (ETR:IJF)
Germany · Delayed Price · Currency is EUR | Market Cap | 9.60B -1.1% |
| Revenue (ttm) | 7.17B +1.9% |
| Net Income | 150.28M -75.7% |
| EPS | 1.92 -74.4% |
| Shares Out | n/a |
| PE Ratio | 63.86 |
| Forward PE | 13.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2 |
| Open | 125.35 |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | 119.25 - 129.75 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 22, 2026 |
About ETR:IJF
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access ... [Read more]
Financial Performance
In 2025, ETR:IJF's revenue was $8.25 billion, an increase of 0.76% compared to the previous year's $8.19 billion. Earnings were $229.34 million, a decrease of -68.97%.
Financial numbers in USD Financial StatementsNews
ICON Public Limited Company Earnings release: Q1 2026
ICON Public Limited Company released its Q1 2026 earnings on June 24, 2026, summarizing the period's financial results.
ICON Public Limited Company Slides: Q1 2026
ICON Public Limited Company has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on June 24, 2026.
Icon reports Q1 adjusted EPS $2.50, consensus $2.43
Reports Q1 revenue $2.034B, consensus $2B. CEO Barry Balfe commented, “ICON (ICLR) maintained strong commercial momentum in quarter one, delivering net bookings of $2.9 billion, and a net book-to-bill...
Notable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include FedEx (FDX), consensus $5.95… Cerebras Systems (CBRS), consensus (16c)… KB Home (KBH), consensus 46c… Icon plc (ICL...
Icon selects Microsoft as preferred technology partner
ICON (ICLR) announced that it has selected Microsoft (MSFT) as a preferred technology partner. This partnership incorporates an enterprise-wide deployment of Microsoft 365 Copilot along with an enterp...
ICON selects Microsoft as a preferred technology partner to power AI-enabled clinical development
DUBLIN--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR) today announced that it has selected Microsoft as a preferred technology partner – further advancing ICON's previously announced plan to invest in digi...
ICON Schedules First Quarter 2026 Earnings Conference Call
DUBLIN--(BUSINESS WIRE)--ICON Schedules First Quarter 2026 Earnings Conference Call.
Icon price target raised to $164 from $120 at TD Cowen
TD Cowen raised the firm’s price target on Icon (ICLR) to $164 from $120 and keeps a Buy rating on the shares. The firm sees the company’s investigation conclusion as…
Icon price target raised to $125 from $105 at BofA
BofA raised the firm’s price target on Icon (ICLR) to $125 from $105 and keeps an Underperform rating on the shares. Following the Q4 report, the firm believes the company…
Icon price target raised to $159 from $139 at Truist
Truist raised the firm’s price target on Icon (ICLR) to $159 from $139 and keeps a Hold rating on the shares after the company’s Q4 results and initial FY26 outlook.
Icon price target raised to $126 from $123 at RBC Capital
RBC Capital raised the firm’s price target on Icon (ICLR) to $126 from $123 and keeps a Sector Perform rating on the shares. The company’s Q4 earnings and restated financials…
Icon price target raised to $165 from $135 at Jefferies
Jefferies raised the firm’s price target on Icon (ICLR) to $165 from $135 and keeps a Buy rating on the shares. Gross bookings momentum and the accounting investigation outcome were…
Icon price target raised to $160 from $130 at BMO Capital
BMO Capital analyst Sean Dodge raised the firm’s price target on Icon (ICLR) to $160 from $130 and keeps an Outperform rating on the shares. The firm is updating its…
Icon price target raised to $130 from $120 at JPMorgan
JPMorgan raised the firm’s price target on Icon (ICLR) to $130 from $120 and keeps a Neutral rating on the shares post the Q4 report. The company reported strong bookings…
Icon price target raised to $140 from $120 at Citi
Citi analyst Patrick Donnelly raised the firm’s price target on Icon (ICLR) to $140 from $120 and keeps a Neutral rating on the shares.
Icon price target raised to $168 from $142 at Baird
Baird raised the firm’s price target on Icon (ICLR) to $168 from $142 and keeps an Outperform rating on the shares.
Icon price target raised to $150 from $120 at Barclays
Barclays raised the firm’s price target on Icon (ICLR) to $150 from $120 and keeps an Equal Weight rating on the shares following the fiscal Q4 report. The estimate “reset…
ICON Public Limited Company Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw strong commercial performance, improved win rates, and robust bookings, despite revenue recognition issues that led to restatements and a $3.9B backlog adjustment. 2026 guidance anticipates revenue of $7.85B–$8.15B and margin improvement, with continued investment in growth areas and AI.
ICON Public Limited Company Annual report: Q4 2025
ICON Public Limited Company has published its Q4 2025 annual report on May 28, 2026.
ICON Public Limited Company Earnings release: Q4 2025
ICON Public Limited Company released its Q4 2025 earnings on May 28, 2026, summarizing the period's financial results.
ICON Public Limited Company Slides: Q4 2025
ICON Public Limited Company has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on May 28, 2026.
ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation
DUBLIN--(BUSINESS WIRE)--ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation.
ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq
DUBLIN--(BUSINESS WIRE)--ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq.
ICON expands US early phase research capabilities with new clinic and outpatient centres
DUBLIN & SAN ANTONIO--(BUSINESS WIRE)--ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced the expansion of its early phase capabilities with the opening of a new,...
HealthVerity to Acquire Symphony Health, Uniting Clinical Data and Commercial Analytics to Accelerate Breakthroughs Across the Healthcare Ecosystem
Philadelphia, PA, May 05, 2026 (GLOBE NEWSWIRE) -- HealthVerity, Inc., the leader in privacy-protected real-world data exchange and patient identity solutions, today announced that it has entered into...